SYK-Independent TREM2 Pathways Remain Functional in TYROBP Deficiency

Target: SYK, TREM2 Composite Score: 0.548 Price: $0.54▼1.3% Citation Quality: Pending neuroinflammation Status: promoted

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🔥 Neuroinflammation 🧠 Neurodegeneration

✓ All Quality Gates Passed

Quality Report Card click to collapse

C+

Composite: 0.548

Top 66% of 1351 hypotheses

T3 Provisional

Single-source or model-inferred

Needs composite score ≥0.60 (current: 0.55) for Supported

C+ Mech. Plausibility 15% 0.55 Top 67%

C+ Evidence Strength 15% 0.50 Top 65%

B Novelty 12% 0.65 Top 64%

B Feasibility 12% 0.60 Top 44%

B Impact 12% 0.60 Top 62%

A Druggability 10% 0.80 Top 21%

B+ Safety Profile 8% 0.70 Top 22%

B Competition 6% 0.65 Top 53%

C+ Data Availability 5% 0.55 Top 60%

C+ Reproducibility 5% 0.55 Top 57%

Evidence

5 supporting | 2 opposing

Citation quality: 75%

Debates

1 session C+

Avg quality: 0.56

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

Why is TYROBP deficiency neuroprotective when TYROBP is an adapter for multiple AD risk receptors?

The abstract shows TYROBP deficiency is neuroprotective despite being required for TREM2, CD33, and CR3 function - receptors associated with AD risk. This counterintuitive finding challenges current understanding of how these immune receptors contribute to AD pathogenesis. Gap type: contradiction Source paper: Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer's pathology. (None, None, PMID:28612290)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (1)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

TREM2 Signaling Bifurcation with Independent TYROBP-Independent Homeostatic Maintenance

Score: 0.591 | Target: TREM2

→ View full analysis & all 2 hypotheses

Description

Mechanistic Overview

...

Mechanistic Overview

SYK-Independent TREM2 Pathways Remain Functional in TYROBP Deficiency starts from the claim that modulating SYK, TREM2 within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview SYK-Independent TREM2 Pathways Remain Functional in TYROBP Deficiency starts from the claim that TREM2 drives microglia response via both SYK-dependent and SYK-independent pathways. The SYK-dependent pathway (TYROBP-dependent) controls phagocytosis and pro-inflammatory responses, while SYK-independent pathways maintain microglial metabolic fitness and survival. TYROBP deficiency selectively blocks SYK-dependent pathology while preserving TREM2's SYK-independent homeostatic functions. Framed more explicitly, the hypothesis centers SYK, TREM2 within the broader disease setting of neuroinflammation. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating SYK, TREM2 or the surrounding pathway space around TREM2 → SYK → PI3K/mTOR phagocytic signaling can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.50, novelty 0.65, feasibility 0.60, impact 0.60, mechanistic plausibility 0.55, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `SYK, TREM2` and the pathway label is `TREM2 → SYK → PI3K/mTOR phagocytic signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. Gene-expression context on the row adds an important constraint: Gene Expression Context TREM2: - TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a lipid-sensing immunoreceptor on microglia that signals through TYROBP/DAP12 to promote phagocytosis while suppressing inflammation. Allen Human Brain Atlas shows exclusive microglial expression with highest density in hippocampus, temporal cortex, and around amyloid plaques. Disease-associated microglia (DAM) are defined by TREM2-high/P2RY12-low expression. SEA-AD data shows TREM2 upregulation (log2FC=+1.5) correlating with Braak stage. Two-stage DAM model: Stage 1 (TREM2-independent) involves downregulation of homeostatic genes; Stage 2 (TREM2-dependent) involves phagocytic gene upregulation (CLEC7A, AXL, LGALS3). R47H variant (OR=2.9-4.5 for AD) reduces ligand binding by ~50%; sTREM2 (soluble) is shed by ADAM10/17 and serves as CSF biomarker. - Allen Human Brain Atlas: Exclusively microglia; highest in hippocampus, temporal cortex, and around amyloid plaques; BAMs also express TREM2 - Cell-type specificity: Microglia (highest, exclusive in CNS), Border-associated macrophages (BAMs), Not expressed in neurons, astrocytes, or oligodendrocytes under homeostatic conditions - Key findings: TREM2-high microglia form physical barrier around dense-core plaques, compacting cores and limiting oligomer diffusion; TREM2 R47H variant (OR=2.9-4.5 for AD) reduces PS/lipid binding by ~50%; sTREM2 in CSF peaks at clinical conversion from MCI to AD, serving as microglial activation biomarker This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance. Within neuroinflammation, the working model should be treated as a circuit of stress propagation. Perturbation of SYK, TREM2 or TREM2 → SYK → PI3K/mTOR phagocytic signaling is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. Identifier 36306735. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. TREM2 mutations prevent PI3K/AKT pathway activation. Identifier 31649511. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. TREM2 maintains microglial survival via metabolic reprogramming. Identifier 40754372. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Differential downstream signaling in microglia lacking Alzheimer's-related TREM2 or its adaptor TYROBP/DAP12. Identifier 41659250. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Endocytosis pathway enriched in AD risk loci (p=0.0003). Identifier computational:ad_genetic_risk_loci. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. The bifurcation model does not explain why TREM2-only knockouts still show DAM deficits if SYK-independent pathways remain functional. Identifier 28612290. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. SYK-independent pathway relates to metabolic fitness, not NFκB antagonism per se - limited anti-inflammatory evidence. Identifier 36306735. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.543`, debate count `1`, citations `7`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 2. Trial context: UNKNOWN. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 3. Trial context: RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates SYK, TREM2 in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "SYK-Independent TREM2 Pathways Remain Functional in TYROBP Deficiency". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting SYK, TREM2 within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers SYK, TREM2 within the broader disease setting of neuroinflammation. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating SYK, TREM2 or the surrounding pathway space around TREM2 → SYK → PI3K/mTOR phagocytic signaling can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.50, novelty 0.65, feasibility 0.60, impact 0.60, mechanistic plausibility 0.55, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `SYK, TREM2` and the pathway label is `TREM2 → SYK → PI3K/mTOR phagocytic signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context TREM2: - TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a lipid-sensing immunoreceptor on microglia that signals through TYROBP/DAP12 to promote phagocytosis while suppressing inflammation. Allen Human Brain Atlas shows exclusive microglial expression with highest density in hippocampus, temporal cortex, and around amyloid plaques. Disease-associated microglia (DAM) are defined by TREM2-high/P2RY12-low expression. SEA-AD data shows TREM2 upregulation (log2FC=+1.5) correlating with Braak stage. Two-stage DAM model: Stage 1 (TREM2-independent) involves downregulation of homeostatic genes; Stage 2 (TREM2-dependent) involves phagocytic gene upregulation (CLEC7A, AXL, LGALS3). R47H variant (OR=2.9-4.5 for AD) reduces ligand binding by ~50%; sTREM2 (soluble) is shed by ADAM10/17 and serves as CSF biomarker. - Allen Human Brain Atlas: Exclusively microglia; highest in hippocampus, temporal cortex, and around amyloid plaques; BAMs also express TREM2 - Cell-type specificity: Microglia (highest, exclusive in CNS), Border-associated macrophages (BAMs), Not expressed in neurons, astrocytes, or oligodendrocytes under homeostatic conditions - Key findings: TREM2-high microglia form physical barrier around dense-core plaques, compacting cores and limiting oligomer diffusion; TREM2 R47H variant (OR=2.9-4.5 for AD) reduces PS/lipid binding by ~50%; sTREM2 in CSF peaks at clinical conversion from MCI to AD, serving as microglial activation biomarker This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within neuroinflammation, the working model should be treated as a circuit of stress propagation. Perturbation of SYK, TREM2 or TREM2 → SYK → PI3K/mTOR phagocytic signaling is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. Identifier 36306735. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

TREM2 mutations prevent PI3K/AKT pathway activation. Identifier 31649511. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

TREM2 maintains microglial survival via metabolic reprogramming. Identifier 40754372. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Differential downstream signaling in microglia lacking Alzheimer's-related TREM2 or its adaptor TYROBP/DAP12. Identifier 41659250. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Endocytosis pathway enriched in AD risk loci (p=0.0003). Identifier computational:ad_genetic_risk_loci. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

The bifurcation model does not explain why TREM2-only knockouts still show DAM deficits if SYK-independent pathways remain functional. Identifier 28612290. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

SYK-independent pathway relates to metabolic fitness, not NFκB antagonism per se - limited anti-inflammatory evidence. Identifier 36306735. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.543`, debate count `1`, citations `7`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: UNKNOWN. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates SYK, TREM2 in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "SYK-Independent TREM2 Pathways Remain Functional in TYROBP Deficiency".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting SYK, TREM2 within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["Disease Pathology"] --> B["Molecular Dysfunction"]
    B --> C["Cellular Damage"]
    C --> D["Neuronal Loss"]
    E["SYK Therapeutic Intervention"] --> F["Pathway Modulation"]
    F --> G["Cellular Function Restoration"]
    G --> H["Neuroprotection"]
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style E fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style H fill:#1b5e20,stroke:#81c784,color:#81c784

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

7 citations 7 with PMID Validation: 75% 5 supporting / 2 opposing

✓ For (5)

No supporting evidence

No opposing evidence

(2) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 3CLIN 1GENE 3EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
TREM2 drives microglia response to amyloid-β via S…	Supporting	MECH	-	-	-	-	PMID:36306735	-
TREM2 mutations prevent PI3K/AKT pathway activatio…	Supporting	GENE	-	-	-	-	PMID:31649511	-
TREM2 maintains microglial survival via metabolic …	Supporting	CLIN	-	-	-	-	PMID:40754372	-
Differential downstream signaling in microglia lac…	Supporting	MECH	-	-	-	-	PMID:41659250	-
Endocytosis pathway enriched in AD risk loci (p=0.…	Supporting	GENE	-	-	-	-	PMID:computational:ad_genetic_risk_loci	-
The bifurcation model does not explain why TREM2-o…	Opposing	GENE	-	-	-	-	PMID:28612290	-
SYK-independent pathway relates to metabolic fitne…	Opposing	MECH	-	-	-	-	PMID:36306735	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 5

TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways

PMID:36306735

TREM2 mutations prevent PI3K/AKT pathway activation

PMID:31649511

TREM2 maintains microglial survival via metabolic reprogramming

PMID:40754372

Differential downstream signaling in microglia lacking Alzheimer's-related TREM2 or its adaptor TYROBP/DAP12

PMID:41659250

Endocytosis pathway enriched in AD risk loci (p=0.0003)

PMID:computational:ad_genetic_risk_loci

✗ Opposing Evidence 2

The bifurcation model does not explain why TREM2-only knockouts still show DAM deficits if SYK-independent pat…▼

The bifurcation model does not explain why TREM2-only knockouts still show DAM deficits if SYK-independent pathways remain functional

PMID:28612290

SYK-independent pathway relates to metabolic fitness, not NFκB antagonism per se - limited anti-inflammatory e…▼

SYK-independent pathway relates to metabolic fitness, not NFκB antagonism per se - limited anti-inflammatory evidence

PMID:36306735

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-15 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Novel Therapeutic Hypotheses: TYROBP Deficiency Paradox in Alzheimer's Disease

Hypothesis 1: CD33-TYROBP Axis Drives Neurotoxicity While TREM2 Uses TYROBP-Independent Pathways for Homeostatic Function

Description: TYROBP deletion achieves neuroprotection primarily by silencing the harmful CD33-mediated suppression of microglial phagocytosis, while TREM2 retains neuroprotective functions through TYROBP-independent compensatory mechanisms. This decouples the pathogenic CD33-TYROBP axis from beneficial TREM2 signaling, explaining why global TYROBP loss is paradoxically protectiv

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of TYROBP Deficiency Paradox Hypotheses

Overarching Methodological Concern

Before evaluating individual hypotheses, a fundamental issue must be addressed: TYROBP loss-of-function variants in humans cause Nasu-Hakola disease (FBD/PLOSL), characterized by early-onset progressive neurodegeneration, bone cysts, and presenile dementia (Paloneva et al., PMID: 11774071). This directly contradicts the premise that TYROBP deficiency is neuroprotective in AD. This tension—mouse model neuroprotection versus human neurodegeneration—pervades all seven hypotheses and represe

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Critical Drug Development Assessment: TYROBP Deficiency Paradox

The Elephant in the Room: Nasu-Hakola Disease

Before evaluating druggability, the human genetics must be addressed squarely. TYROBP loss-of-function causes Nasu-Hakola disease (FBD/PLOSL)—an autosomal recessive disorder characterized by:

Demyelination and neurodegeneration beginning in 3rd-4th decade
Bone cysts and fractures
Progressive cognitive decline leading to dementia
Death typically by age 50

This directly contradicts the premise that TYROBP inhibition could be therapeutic. The skeptic critique correc

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↔

Stable

7d Momentum

▲ 0.0%

Volatility

Low

0.0070

Events (7d)

⚡ Price Movement Log Recent 12 events

	Event	Price	Change	Source	Time
💬	Debate Round	$0.331	▼ 53.6%	market_dynamics	2026-04-15 17:31
💬	Debate Round	$0.714	▲ 68.0%	market_dynamics	2026-04-15 17:04
💬	Debate Round	$0.425	▼ 27.0%	market_dynamics	2026-04-15 14:25
📄	New Evidence	$0.582	▲ 10.6%	market_dynamics	2026-04-15 12:58
📊	Score Update	$0.527	▲ 4.4%	market_dynamics	2026-04-15 11:59
📊	Score Update	$0.504	▼ 21.4%	market_dynamics	2026-04-15 10:25
📊	Score Update	$0.642	▲ 11.5%	market_dynamics	2026-04-15 10:22
📄	New Evidence	$0.576	▲ 6.9%	market_dynamics	2026-04-15 09:57
📄	New Evidence	$0.538	▼ 6.4%	market_dynamics	2026-04-15 09:56
📄	New Evidence	$0.575	▼ 6.5%	evidence_update	2026-04-15 05:50
📄	New Evidence	$0.615	▲ 11.9%	evidence_update	2026-04-15 05:50
✨	Listed	$0.550		post_process	2026-04-15 05:50

Clinical Trials (5)

0
Active

0
Completed

709
Total Enrolled

PHASE1
Highest Phase

Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients PHASE2

COMPLETED · NCT04388254 · Cassava Sciences, Inc.

220 enrolled · 2020-03-24 · → 2023-11-09

Alzheimer Disease

Simufilam 100 mg oral tablet Placebo

Hyperhomocysteinemia in Alzheimer's Disease Unknown

UNKNOWN · NCT05793372 · Central Hospital, Nancy, France

43 enrolled · 2023-06 · → 2023-06

Alzheimer Disease Homocystinemia

Retrospective study of clinical features

The Signature of Alzheimer's Disease in Subjective Cognitive Decline Unknown

RECRUITING · NCT07402161 · IRCCS Policlinico S. Donato

250 enrolled · 2025-10-01 · → 2027-10-01

Subjective Cognitive Decline (SCD) Subjective Cognitive Complaints (SCCs) Subjective Cognitive Impairment

Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers PHASE1

COMPLETED · NCT04570644 · AZTherapies, Inc.

56 enrolled · 2020-08-28 · → 2021-01-18

Healthy Volunteers Alzheimer Disease

ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)

Activity of Cerebral Networks, Amyloid and Microglia in Aging and Alzheimer's Disease Unknown

COMPLETED · NCT06224920 · Ludwig-Maximilians - University of Munich

140 enrolled · 2017-01-01 · → 2024-01-01

Alzheimer Disease Corticobasal Syndrome

magnetic resonance imaging electroencephalography blood and CSF biomarker

📚 Cited Papers (6)

Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer's pathology.

Acta neuropathologica (2017) · PMID:28612290

No extracted figures yet

Distinct Signaling Pathways Regulate TREM2 Phagocytic and NFκB Antagonistic Activities.

Frontiers in cellular neuroscience (2020) · PMID:31649511

No extracted figures yet

TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways.

Cell (2022) · PMID:36306735

No extracted figures yet

Facilitating microglial phagocytosis by which Jiawei Xionggui Decoction alleviates cognitive impairment via TREM2-mediated energy metabolic reprogramming.

Chin J Nat Med (2025) · PMID:40754372

No extracted figures yet

Differential downstream signaling in microglia lacking Alzheimer's-related TREM2 or its adaptor TYROBP/DAP12.

Molecular neurodegeneration advances (2026) · PMID:41659250

No extracted figures yet

Paper:computational:ad_genetic_risk_loci

No extracted figures yet

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

KG Entities (2)

SYK, TREM2 neuroinflammation

Related Hypotheses

IL-6 Trans-Signaling Blockade at the Oligodendrocyte-Microglia Interface

Score: 0.806 | neuroinflammation

STING Antagonists as ALS Therapeutics: Drug Repurposing

Score: 0.740 | neuroinflammation

PDE4 Inhibition as Inflammatory Reset for PD Oligodendrocytes

Score: 0.734 | neuroinflammation

TREM2 Crosstalk and Synergistic Activation of Phagocytic Transcriptome

Score: 0.730 | neuroinflammation

Temporal SPP1 Inhibition During Critical Windows

Score: 0.728 | neuroinflammation

Estimated Development

Estimated Cost

Timeline

2.0 years

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (1 edges)

promoted: SYK-Independent TREM2 Pathways Remain Functional in TYROBP Deficiency (1)

SYK, TREM2→neuroinflammation

3D Protein Structure

🧬 SYK — Search for structure Click to search RCSB PDB

🔍 Searching RCSB PDB for SYK structures...

Querying Protein Data Bank API

Source Analysis

Why is TYROBP deficiency neuroprotective when TYROBP is an adapter for multiple AD risk receptors?

neuroinflammation | 2026-04-14 | archived

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)